Takeda is set to evaluate a cargo ship powered by wind energy.

Takeda Pharmaceutical has partnered with Vela, a shipping startup, to trial a wind-powered cargo vessel for transporting temperature-sensitive drugs between France and the U.S., aiming for a two-week delivery timeline. The initial voyage, carrying Takeda’s blood-disease medication, is planned for fall 2026. Takeda intends to ship 5% of its volumes in 2026 while ensuring compliance with Good Distribution Practice standards. Vela’s vessels aim to reduce shipping costs, avoid congestion, and help Takeda achieve its net-zero emissions target by 2040. Future plans include expanding Vela's fleet and services.